Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Cell cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Markers for pre-cancer and cancer calls and the method to interfere with cell proliferation therein
A novel family of human mitochondrial RNAs, referrred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therrefore, a novel approach for cancer therapy.
Owner:ANDES BIOTECH
Novel use of niclosamide and pharmaceutically acceptable salt thereof
InactiveCN101254183AGood curative effectImproved prognosisOrganic active ingredientsAntineoplastic agentsProstate cancerTherapeutic effect
The invention discloses an application of niclosamide or pharmaceutically-acceptable salts thereof in preparing anti-tumor drugs, which provides a candidate drug for tumor patients and may further improve the therapeutic effect and the prognosis to patients. The effectiveness of niclosamide or pharmaceutically-acceptable salts thereof on various tumor cells indicates that the composition may be used for treating various cancers such as cerebroma, genitourinary tumor, lymphatic system, stomach cancer, cancer of larynx, nasopharyngeal cancer, skin cancer, bone cancer, leukaemia, leukaemia, breast cancer, histiocytic lymphoma, non-small-cell lung cancer, small-cell lung cancer, lung adenocarcinoma, epidermoid cancer, pancreatic cancer, prostatic cancer, liver cancer and epithelial cell cancer.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Diagnosis and treatment of myeloid and lymphoid cell cancers
InactiveUS20110311445A1Prevent degradationOrganic active ingredientsHeavy metal active ingredientsCell cancerLymphocyte
Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and / or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.
Owner:MORPHOTEX INC
Substituted benzamide compounds and preparation method and application thereof
InactiveCN102531949AImprove bioavailabilityGood antitumor activityOrganic active ingredientsOrganic compound preparationBladder cancerCell cancer
The invention relates to substituted benzamide compounds shown as a general formula (I) or medicinal salts thereof, preparation of the compounds or the medicinal salts thereof, a medicament composition containing the compounds or the medicinal salts thereof and application of the compounds in treatment of cancers, in particular application in treatment of head and neck cancers, non-small cell lung cancer, pancreatic cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer and flat cell cancer and application in medicaments for treating the cancers.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-i inhibiting antibody-drug conjugate (ADC) targeting trop-2
ActiveUS20180185351A1Good effectLow toxicityOrganic active ingredientsHeavy metal active ingredientsCarboplatinLymphatic Spread
The present invention relates to treatment of SCLC with therapeutic ADCs comprising a drug attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody is an hRS7 antibody and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg / kg and 16 mg / kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg / kg, mostly preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the ADC is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan. Preferably, the ADC is administered as a combination therapy with one or more other anti-cancer treatments, such as carboplatin or cisplatinum.
Owner:IMMUNOMEDICS INC
Kit for forecasting NSCLC (non-small-cell lung cancer) patient prognosis and application of osteopontin acting as specific marker
InactiveCN103926408AImprove long-term survival rateImproved prognosisDisease diagnosisBiological testingCell cancerImmunofluorescence
The invention discloses a kit for constructing forecasting NSCLC (non-small-cell lung cancer) patient prognosis and guiding clinic application of zoledronic acid and application of osteopontin (OPN) acting as a specific marker of M2 type macrophage; the application of the kit provided by the invention is evaluation of the NSCLC patient prognosis by using the expression of OPN in an immunofluorescence double standard technology detection tissue chip in TAMs and tumor cells, and comprehensive measures are taken in real time to interfere aiming at the detection result of the kit, so that the long-term survival rate of patients is increased, and the prognosis is improved; the method is simple and convenient and can be widely applied to clinic.
Owner:TIANJIN MEDICAL UNIV CANCER INST & HOSPITAL
Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
InactiveUS20100196886A1High affinityStrong specificitySugar derivativesMicrobiological testing/measurementCell cancerCancer cell
A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and / or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and / or miR-150.
Owner:ROSALIND FRLIN UNIV OF MEDICINE & SCI AN ILLINOIS +1
Cell line for lowly-metastatic clear cell carcinoma of kidney of Han Chinese
InactiveCN101550407AMicrobiological testing/measurementMicroorganism based processesCancer cellKidney
The invention discloses a cell line for lowly-metastatic clear cell carcinoma of kidney of Han Chinese, namely LoMeT-ccRcc CCTCC No.C200910. The cell line can grow for a long time in vitro and be stably handed down, has epithelioid cell form, and has no contact inhibition. The cell is heteroploid, chromosome number and structure are aberrant. Immunohistochemistry shows masculine CA9 and CD133. A flow cytometry analyses and finds out that CA9 and CD133 expression is obviously enhanced in the condition that cell is handed down for many times. The cell line has lowly-metastatic trend after the cell is handed down continuously. The recovery rate of the cell line after being frozen is more than 80%, the recovered cell growth state accords with the original cell. The cell line of the invention is used for establishing a cell model for sieving and preparing medicines that is used for dialogising, preventing and treating clear cell carcinoma of kidney.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Biomarker relating to renal clear cell carcinoma
ActiveCN107496923APrecision therapyAchieve early detectionOrganic active ingredientsGenetic material ingredientsCell cancerCancer cell
The invention discloses a biomarker relating to renal clear cell carcinoma. The biomarker is SLC17A9. Experiments prove that the expression of the SLC17A9 is up-regulated in patients suffering from the renal clear cell carcinoma, proliferation and invasion of the renal clear cell carcinoma cells can be inhibited, and the SLC17A9 can serve as a diagnosis and / or treatment target to be applied to clinical renal clear cell carcinoma diagnosis and treatment.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD
Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
InactiveUS7563570B2High sensitivityImprove survivalHeavy metal active ingredientsSugar derivativesCell cancerRegimen
The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy.
Owner:PANGAEA BIOTECH
Medicine for treating advanced non-small-cell lung cancer and preparation method of medicine
ActiveCN106620391AInhibit aggregationGrowth inhibitionUnknown materialsAntineoplastic agentsLife qualityFritillaria thunbergii
The invention discloses a medicine for treating advanced non-small-cell lung cancer and a preparation method of the medicine. The medicine for treating advanced non-small-cell lung cancer is prepared from raw materials in parts by weight as follows: 20-40 parts of hedyotis diffusa, 20-40 parts of scutellaria barbata, 20-40 parts of herba houttuyniae, 10-20 parts of dried tangerine peel, 20-30 parts of fructus trichosanthis, 10-20 parts of semen coicis, 20-30 parts of semen lepidii, 10-20 parts of radix scutellariae, 10-20 parts of rhizoma anemarrhenae, 10-20 parts of semen armeniacae amarae, 10-20 parts of bulbus fritillaria thunbergii, 20-30 parts of carapax trionycis, 10-20 parts of prunella vulgaris, 20-40 parts of radix astragali, 10-20 parts of codonopsis pilosula, 10-20 parts of rhizoma phragmitis, 10-20 parts of semen persicae, 10-15 parts of fructus perillae and 5-10 parts of radix glycyrrhizae preparata. The medicine has the effects of clearing heat, removing toxins, reducing phlegm, removing blood stasis, tonifying qi and nourishing yin and has functions of resisting tumor, relieving cough, eliminating phlegm and enhancing body immunity. The medicine capsules can relieve symptoms of patients, have exact curative effect and can prolong lifetime of the patients and improve the life quality.
Owner:平阴县中医医院
Application of micro peptide CIP2A-BP in treatment of cancer
ActiveCN110064045AInhibit transferPrevent invasionPeptide/protein ingredientsAntineoplastic agentsCell cancerIn vivo experiment
The invention relates to application of micro peptide CIP2A-BP in treatment of cancer. From the prospective of translating horizontal IncRNA codes, the influence of the micro peptide on the malignantbiological behaviors of breast cancer cell transferring and migration is studied. By means of treatment of the targeted micro peptide CIP2A-BP, B56 gamma subunits of the micro peptide CIP2A-BP and PP2A are competitively bound with cell cancer genes CIP2A, and therefore PP2A activity is released, activation of a PI3K / AKT / NF kappa B access is inhibited, and consequently the expression level of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and EMT induced transcription factors Snail is reduced. It is proved through in-vitro and in-vivo experiments that migration and invasion of breast cancer cells can be obviously inhibited through micro peptide CIP2A-BP, and the micro peptide CIP2A-BP has clinical application value on breast cancer.
Owner:SUZHOU UNIV
Application of rna polymerase ii fifth subunit regulatory protein in preparation of reagents for hepatocellular carcinoma prognosis or auxiliary tace prognosis
The invention relates to an application of an RNA (Ribose Nucleic Acid) polymerase II fifth subunit regulatory protein (RMP) in preparation of a reagent for prognosis of hepatocellular carcinoma or auxiliary TACE (Transcatheter Arterial Chemoembolization). The invention firstly reveals that high expression of the RMP in a hepatic cell cancer indicates unsatisfactory prognosis of resection of hepatocellular carcinoma after operation; meanwhile, the high expression of the RMP further indicates that the auxiliary TACE after operation is effective. Thus, the invention establishes an RMP-based prognosis method of the hepatic cell cancer after operation.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
InactiveUS20120083503A1Good treatment effectProlonged progression-free survivalBiocidePeptide/protein ingredientsCarboplatinCell cancer
This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur / gimeracil / oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene.
Owner:KINKI UNIVERSITY +1
Plasma metabolization micromolecule marker related to human non-small-cell lung cancer and application of plasma metabolization micromolecule marker
InactiveCN105203683ARepair inhibitionIncrease contractilityComponent separationMetaboliteConfidence interval
The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.
Owner:JIANGSU PROVINCE HOSPITAL
Kit for judging therapeutic response of NSCLC (non-small-cell lung cancer) patient to gefitinib
ActiveCN104131102AEasy to detectThe test results are consistentMicrobiological testing/measurementCell cancerMedicine
The invention discloses a kit for judging therapeutic response of an NSCLC (non-small-cell lung cancer) patient to gefitinib. The kit comprises a reagent capable of being used for detecting the genotypes of an rs9912773 site and / or an rs1294991 site in an STAT3 gene. According to the kit, correlation analysis of therapeutic response of an SNP (single nucleotide polymorphism) site of the STAT3 gene and the gefitinib to the advanced NSCLC through genetic typing of the patient discovers that the therapeutic response of the NSCLC patient to the gefitinib can be judged according to the genotypes of the rs9912773 site and / or the rs1294991 site. The development of the kit provides a reliable and sensitive way for determining a therapy scheme of the advanced NSCLC patient.
Owner:马飞
Identification method of group of genomic characteristic mutation fingerprints associated with homologous recombination repair defects
The present invention discloses a genomic characteristic mutation fingerprint related to hHRD type homologous recombination repair defects and comprises a combination characteristic of a single nucleotide variation (SNV) and insertion deletion (Indel) genomic fingerprint, and an identification method thereof. The fingerprint characteristics can be subjected to high-throughput whole-genome resequencing, bioinformatics software analysis and statistical correlation analysis and are used to identify infectious diseases or tumors with the characteristic mutation fingerprints, especially hepatitis Bvirus infection and related diseases, including liver cirrhosis, liver fibrosis and liver cancer. The mutation fingerprint can also be used to guide methods and uses of treatments of targeted drugs targeting the homologous recombination defects on a variety of the various tumors with the hHRD homologous recombination repair defects, including but not limited to breast cancer, ovarian cancer, endometrial cancer, endometrioid carcinoma, ovarian clear cell carcinoma, prostate cancer, gastric cancer, skin cancer, hepatitis B virus infection or related liver cirrhosis, liver cancer and bile duct cell cancer.
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN +1
Dendritic cell vaccine and preparation method and application of dendritic cell vaccine
ActiveCN105031632AGenetic manipulation worksImprove securityDigestive systemBlood/immune system cellsFreeze thawingSide effect
The invention relates to the technical field of medical biology engineering, in particular to a dendritic cell vaccine and a preparation method and application of the dendritic cell vaccine. Disclosed is a method for preparing a dendritic cell (DC) cancer vaccine for persons with liver cancer stem cells. The method comprises the following steps of inserting Oct4 and Sox2 genes in an AAVSl locus of a hepatoma cell line genome by using a zinc finger nuclease technology; enriching similar liver cancer stem cells in corrected liver cancer cells by using a tumor stem cell spheroid forming method; and separating prepared dendritic cells by stimulating autologous blood through similar liver cancer stem cell freeze thawing and cracking liquid to obtain antigen presentation DC cells loaded with liver cancer stem cell antigens. Established liver cancer stem cell strains can express molecular markers of the liver cancer stem cells at a high level, expression of a plurality of liver cancer stem cell markers such as CDl3, CD90, EpCAM and the like can be improved obviously, and the specificity is high; the used antigen presentation dendritic cells source from the autologous blood, are high in safety and have little toxic and side effects; and after being tried out, the prepared DC cell cancer vaccine can obviously stimulate CTL (cytotoxic T lymphocyte ) reaction of the specificity cell toxic effect of the tumor stem cells.
Owner:杭州朔溪生物医药有限公司
Application of combination of tripterine and erastin to medicine for treating non-small-cell lung cancer
ActiveCN109771428AEasy to useGood effectOrganic active ingredientsAntineoplastic agentsCell cancerCancer cell
The invention discloses application of a combination of tripterine and erastin to medicine for treating a non-small-cell lung cancer. Experiments verify that tripterine of 1-5 microns and erastin of 1.25-5 microns are combined to treat cells of the non-small-cell lung cancer, so that the cells of the cancer are remarkably induced to die, the survival rate of the cells of the cancer is decreased, accordingly, the effect of treating the lung cancer is realized, and an important conception is provided for clinical treatment of the lung cancer.
Owner:HEBEI NORMAL UNIV
Application of monoclonal antibody NJ001-1 to preparation of drug for inhibiting invasion and metastasis of NSCLC (non-small-cell lung cancer)
ActiveCN105126098AInhibit transferHigh expressionAntibody ingredientsAntineoplastic agentsAntigenLymphatic Spread
The invention discloses application of a monoclonal antibody NJ001-1 to preparation of a drug for inhibiting invasion and metastasis of NSCLC (non-small-cell lung cancer). The monoclonal antibody NJ001-1 is secreted by a hybridoma cell strain NM001-1 with the preservation number CCTCC NO: C201172. The monoclonal antibody NJ001-1 is capable of inhibiting migration and invasion of lung adenocarcinoma cells effectively and increasing TIMP-3mRNA and protein expression remarkably. Under the action of the monoclonal antibody NJ001-1, specific antigen of the monoclonal antibody NJ001-1 can be combined with transcription factors FOXP1 (forkhead box protein P1 ) in lung adenocarcinoma cell nucleuses to inhibit transcription inhibition effect on a TIMP-3 gene promoter region.
Owner:NANJING MARKERLINE BIOMEDICAL TECH CO LTD
Application of RNA (Ribose Nucleic Acid) polymerase II fifth subunit regulatory protein in preparation of reagent for prognosis of hepatocellular carcinoma or auxiliary TACE (Transcatheter Arterial Chemoembolization)
The invention relates to an application of an RNA (Ribose Nucleic Acid) polymerase II fifth subunit regulatory protein (RMP) in preparation of a reagent for prognosis of hepatocellular carcinoma or auxiliary TACE (Transcatheter Arterial Chemoembolization). The invention firstly reveals that high expression of the RMP in a hepatic cell cancer indicates unsatisfactory prognosis of resection of hepatocellular carcinoma after operation; meanwhile, the high expression of the RMP further indicates that the auxiliary TACE after operation is effective. Thus, the invention establishes an RMP-based prognosis method of the hepatic cell cancer after operation.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
InactiveUS8841436B2Small sizeHigh affinitySugar derivativesMicrobiological testing/measurementCell cancerCancer cell
Owner:ROSALIND FRLIN UNIV OF MEDICINE & SCI AN ILLINOIS +1
Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
InactiveUS8598188B2Good treatment effectConducive to survivalBiocidePeptide/protein ingredientsCarboplatinCell cancer
Owner:KINKI UNIVERSITY +1
P70 s6 kinase inhibitor and mtor inhibitor combination therapy
The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.
Owner:ELI LILLY & CO
Kit for predetermining treatment effect of iressa on patient with non-small-cell lung cancer by using FAS-1377G/A
InactiveCN102251030AImprove graspOptimize detection resultsMicrobiological testing/measurementDNA/RNA fragmentationTherapeutic effectA-DNA
The invention discloses a kit for predetermining treatment effect of iressa on patient with non-small-cell lung cancer by using FAS-1377G / A. The invention provides special primers which form a primer pair used for amplifying a segment containing FAS-1377G / A, in particular a primer pair formed by a DNA fragment represented by a sequence 1 and a DNA segment represented by a sequence 2. The use of the special primers to help to predict the treatment effect of iressa on non-small-cell lung cancer in the patient has the following advantages: 1, a detection sample may from nucleated cells of any normal or tumor tissue, so almost all patient can obtain a detection sample; 2, FAS-1377G / A belongs to hereditary variation, and the detection result is free from any influence of the sampling time and place; 3, the detection process flow is relative simple and convenient, the equipment requirement is low and the cost is low; and 4, the sensibility is much higher than that of genetic mutation, the detection result is more beneficial to the patient receiving the prediction, and thus, the kit can better meet current sanitary and economic requirements of China.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
DNA fragment for peculiarly inhibiting Rab27B gene expression and application thereof
ActiveCN101787366BDown-regulation of expressionDecreased proliferative ability in vitroGenetic material ingredientsAntineoplastic agentsCancer cellIntein
The invention discloses a DNA fragment for peculiarly inhibiting Rab27B gene expression and the application thereof. A small interfering RNA provided by the invention is of a double-stranded RNA consisting of nucleotide sequences indicated by sequences 4 and 5 in a sequence table. The DNA fragment is shown in formula I, and SEQ forward nucleotide sequence is shown as sequence 2 in the sequence table; the SEQ reverse is complementary with the SEQ forward in opposite directions; and X is of an intron. The experiment approves that: when the DNA fragment is introduced to hepatic cell cancer cell, the Rab27B expressed protein is remarkably reduced, and the vitro proliferation capacity, vitro adhesion capacity, vitro migration capacity and vitro invasive capacity of HCC97H cell are remarkably reduced after the Rab27B is reduced. SEQ FORWARD - X - SEQ REVERSE (I).
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Health drink with anti-cancer function
InactiveCN109832516AInhibition of activationActivation resistanceFood scienceBiotechnologyCell cancer
The invention relates to a health drink with anti-cancer function and a preparation method thereof, which relate to the health drink. Polyphenol substances in suaeda salsa are the excellent anticancersubstances, which can inhibit the activation of carcinogens and resist cell cancer, and combine with hawthorn, rose, bamboo leaves, honeysuckle, mulberry and the like, the product can prevent the spread of cancer cells and realize normal cell growth, and frequent drinking of the drink has anti-cancer and anti-cancer effects.
Owner:盘锦红海碱蓬食品有限公司
Furanone derivatives, preparation methods and uses
The invention relates to a novel selective cyclooxygenase-2 inhibitor compound, a preparation method and use and belongs to the field of chemical drugs. The compound represented by a formula (I) shown in the description can be used for inhibiting cyclooxygenase and interfering with the biotransformation of in-vivo arachidonic acid to prostaglandin, so that the compound and pharmaceutical compositions thereof can be used for treating cyclooxygenase mediated related diseases, i.e., can be used for treating and relieving animal and human inflammations and inflammation caused various diseases such as arthritis, neurodegenerative disease, depression, schizophrenia disease and cancers (including non-small-cell lung cancer, liver cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostatic cancer, cervical cancer, skin cancer, head and neck cancer and the like).
Owner:BEIJING ORBIEPHARM
P70 S6 kinase inhibitor and MTOR inhibitor combination therapy
The present invention provides a compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidine-1- combination therapy of ]-1H-pyrazolo[3,4-d]pyrimidine or a pharmaceutically acceptable salt thereof and an mTOR inhibitor for the treatment of glioblastoma multiforme, colon adenocarcinoma, non-small cell lung cancer , small cell lung cancer, cisplatin-resistant small cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, breast cancer, renal cell carcinoma, multiple myeloma, Kaposi's sarcoma, Hodgkin's lymphoma, Lymphangioleiomyoma, non-Hodgkin lymphoma, or sarcoma.
Owner:ELI LILLY & CO
A kind of dendritic cell vaccine and its preparation method and application
ActiveCN105031632BGenetic manipulation worksInhibitory activityDigestive systemBlood/immune system cellsFreeze thawingCellular antigens
Owner:杭州朔溪生物医药有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com